BioSpace News Archive

Eligo Bioscience SA announced that it has entered into a research and option agreement with GlaxoSmithKline aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

Strong pipeline progress in 2020 positions company well for 2021 Established proof of concept in SCD for FT-4202 Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants Completed successful IPO and follow-on equity offering

The technology, developed by scientists at Memorial Sloan Kettering Cancer Center (“MSKCC”), headed by Dr. Michel Sadelain and Errant Gene Therapeutics, is a one-time treatment that inserts an encoded gene into a patient’s own bone marrow stem cells restoring the production of normal hemoglobin

Elanco Animal Health Incorporated announced that executive vice president of Transformation and Technology, Sarena Lin, will take a role outside of the company at the end of January.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials.

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for its clinical product candidate, cavrotolimod (AST-008), for two development programs:

- Large market partnering program now underway - - Limited COVID-19 impact: Phase III program slated to start in second half of 2021 - - U.S. institutional outreach expanding -

Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer.

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors.